Analytical Data
-
Gene name
CD109/CPAMD7
- Application
-
Alternative Names
CPAMD7; p180; r150; Gov platelet alloantigens; 150 kDa TGF-beta-1-binding protein; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 7
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
D4A447
-
Expression Region
Ile719~Arg965
-
Molecular Weight
31kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD109, also known as CPAMD7, is a glycosylphosphatidylinositol-anchored protein that plays a crucial role in various biological processes, including cell differentiation, immune response, and cancer progression. Initially identified for its involvement in regulating hematopoietic stem cells, CD109 has garnered significant attention due to its aberrant expression in numerous cancers, including lung, breast, and colorectal cancers. Research indicates that CD109 can modulate signaling pathways, such as TGF-β, influencing cellular behaviors like proliferation and migration. The interest in producing recombinant CD109/CPAMD7 protein stems from the need to explore its functional roles and mechanisms in a controlled laboratory setting. By generating this protein, researchers aim to investigate its potential as a biomarker for cancer diagnostics and a target for therapeutic interventions. Understanding its structure and interactions may unveil novel insights into tumor biology and assist in the development of innovative cancer treatments. Hence, the study of recombinant CD109/CPAMD7 not only contributes to the fundamental knowledge of cancer biology but also holds promise for translational applications in oncology.
